Mirum Pharmaceuticals reports Q2 EPS (12c), consensus (33c)

Reports Q2 revenue $128M, consensus $108.1M. “Our second quarter results once again underscore the strength of our commercial programs with notable outperformance from our International business and U.S. PFIC launch,” said Chris Peetz, chief executive officer of Mirum. “The momentum we are seeing with Livmarli globally reinforces our belief that the medicine will reach and help more patients than we initially projected, allowing us to raise guidance with confidence.” Peetz added, “We are carrying that same momentum into our pipeline, where we are on course for three important late stage clinical milestones in 2026. Notably, the VISTAS study of volixibat in PSC will complete enrollment this quarter, and we plan to report topline data in the second quarter of next year.”